We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
-16.4%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$153M
AUM Growth
-$5.06M
Cap. Flow
+$34.5M
Cap. Flow %
22.6%
Top 10 Hldgs %
55.32%
Holding
88
New
19
Increased
22
Reduced
12
Closed
21

Top Buys

Rank Stock Value
1
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$3.19M
2
GDX icon
VanEck Gold Miners ETF
GDX
+$2.46M
3
VZ icon
Verizon
VZ
+$1.43M
4
CSCO icon
Cisco
CSCO
+$1.43M
5
GDXJ icon
VanEck Junior Gold Miners ETF
GDXJ
+$1.33M

Top Sells

Rank Stock Value
1
HD icon
Home Depot
HD
+$2.18M
2
M icon
Macy's
M
+$1.27M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.27M
4
OVV icon
Ovintiv
OVV
+$1.02M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$773K

Sector Composition

Rank Sector Weight
1 Healthcare 30.69%
2 Technology 14.56%
3 Communication Services 8.94%
4 Financials 6.48%
5 Consumer Discretionary 1.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$30.5M 19.98%
118,500
+113,500
+2,270% +$34.6M
GLD icon
2
SPDR Gold Trust
GLD
$131B
$9.62M 6.3%
65,000
– –
GOOG icon
3
Alphabet (Google) Class C
GOOG
$4.36T
$7.5M 4.91%
129,000
+14,000
+12% +$950K
MU icon
4
Micron Technology
MU
$930B
$6.83M 4.47%
162,500
+12,500
+8% +$650K
ITCI
5
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.65M 4.35%
432,500
-35,573
-8% -$773K
REGN icon
6
Regeneron Pharmaceuticals
REGN
$78.5B
$5.93M 3.88%
12,150
-1,250
-9% -$516K
ABBV icon
7
AbbVie
ABBV
$443B
$4.96M 3.25%
65,150
+6,550
+11% +$558K
INCY icon
8
Incyte
INCY
$24.2B
$4.38M 2.86%
59,800
+14,800
+33% +$1.12M
ORCL icon
9
Oracle
ORCL
$374B
$4.11M 2.69%
85,000
+20,000
+31% +$1.03M
T icon
10
AT&T
T
$159B
$4.02M 2.63%
182,712
-15,888
-8% -$434K
AMD icon
11
Advanced Micro Devices
AMD
$776B
$3.87M 2.53%
85,000
– –
BAC icon
12
Bank of America
BAC
$435B
$3.56M 2.33%
167,500
+7,500
+5% +$225K
BMY icon
13
Bristol-Myers Squibb
BMY
$133B
$3.29M 2.15%
59,000
-500
-0.8% -$30.6K
ARGX icon
14
argenx
ARGX
$53.4B
$3.16M 2.07%
24,000
+2,000
+9% +$293K
C icon
15
Citigroup
C
$222B
$3.16M 2.07%
75,000
– –
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$27.5B
$3.16M 2.07%
29,000
-11,000
-28% -$1.27M
IAU icon
17
iShares Gold Trust
IAU
$62.9B
$3.01M 1.97%
100,000
– –
BRK.B icon
18
Berkshire Hathaway Class B
BRK.B
$1.1T
$2.74M 1.79%
+15,000
New +$3.19M
AMGN icon
19
Amgen
AMGN
$208B
$2.69M 1.76%
13,250
+750
+6% +$164K
GLD icon
20
PUT
SPDR Gold Trust
GLD
$131B
$2.59M 1.7%
+17,500
New +$2.61M
XNCR icon
21
Xencor
XNCR
$1.5B
$2.51M 1.64%
84,000
+27,575
+49% +$914K
T icon
22
PUT
AT&T
T
$159B
$2.49M 1.63%
+113,202
New +$3.09M
FMS icon
23
Fresenius Medical Care
FMS
$13.8B
$2.18M 1.43%
66,500
+29,000
+77% +$1.08M
VZ icon
24
Verizon
VZ
$195B
$2.15M 1.41%
40,000
+25,000
+167% +$1.43M
GDX icon
25
VanEck Gold Miners ETF
GDX
$22.7B
$2.07M 1.36%
+90,000
New +$2.46M
1
2 3 4

Similar funds

JIC
JRM Investment Counsel Omaha, Nebraska $375M AUM 13.43% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
AIM
Access Investment Management Atlanta, Georgia $376M AUM 17.2% 1-Year Est. Return
MWM
McMill Wealth Management Norfolk, Nebraska $376M AUM 14.46% 1-Year Est. Return
RCP
RIT Capital Partners London, United Kingdom $374M AUM 25.18% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
CAG
Compass Advisory Group Melville, New York $374M AUM 14.59% 1-Year Est. Return
LWMNY
Landmark Wealth Management (New York) Melville, New York $373M AUM 12.01% 1-Year Est. Return

DCF Advisers's Q1 2020 Portfolio in Review

As of Q1 2020, DCF Advisers held 88 positions worth $153M, down 3.2% from $158M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

DCF Advisers deployed $34.5M of net new capital in Q1 2020, opening 19 new positions and adding to 22 existing holdings. Its largest new stake was Berkshire Hathaway Class B: 15,000 shares worth $2.74M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 37% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $1.27M trimmed.

  • DCF Advisers's largest Q1 2020 buy was Berkshire Hathaway Class B: 15,000 shares worth $2.74M.
  • DCF Advisers added most to Verizon in Q1 2020, an estimated $1.43M increase.
  • DCF Advisers's biggest Q1 2020 reduction was Alnylam Pharmaceuticals, cutting an estimated $1.27M.
  • DCF Advisers fully exited Home Depot in Q1 2020, selling an estimated $2.18M.
  • DCF Advisers's ten largest holdings make up 55% of its $153M portfolio in Q1 2020.
  • DCF Advisers opened 19 new positions and closed 21 in Q1 2020.
  • DCF Advisers's portfolio value fell 3.2% quarter-over-quarter to $153M.

Based on DCF Advisers's 13F filing for Q1 2020, filed 12 May 2020.